Allogene (ALLO): Belldegrun Reports 12.6M Shares (5.7% Stake) Update

Q: How many Allogene (ALLO) shares does Arie Belldegrun report beneficially owning?

The filing reports 12,605,894 shares beneficially owned by Dr. Arie Belldegrun.

Q: What percent of Allogene does Dr. Belldegrun's holding represent?

The reported position represents 5.7% of Allogene's common stock based on 218,730,809 shares outstanding.

Q: Are there option shares included in the reported holdings for ALLO?

Yes. The filing includes 3,243,004 shares issuable within 60 days upon exercise of stock options.

Q: Which affiliated entities hold Allogene shares on behalf of Dr. Belldegrun?

Affiliated entities listed include Bellco Legacy IV LLC (4,710,120) , Bellco Legacy LLC (539,867) , Vida Ventures LLC (1,798,163) , Vida Ventures III, L.P. (1,720,172) , and Vida Ventures III-A, L.P. (3,965) .

Q: What voting and dispositive powers are reported in the filing?

The cover page reports 3,833,607 shares of sole voting power and 8,772,287 shares of shared voting power; sole and shared dispositive powers match those figures.

[SCHEDULE 13G/A] Allogene Therapeutics, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13G/A

Rhea-AI Filing Summary

The Schedule 13G/A discloses that Dr. Arie Belldegrun beneficially owns 12,605,894 shares of Allogene Therapeutics common stock, representing 5.7% of the class based on 218,730,809 shares outstanding. The reported holdings include 3,243,004 shares issuable within 60 days upon exercise of stock options and equity held through related entities: Bellco Legacy IV LLC (4,710,120), Bellco Legacy LLC (539,867), Vida Ventures LLC (1,798,163), Vida Ventures III, L.P. (1,720,172) and Vida Ventures III-A, L.P. (3,965).

Dr. Belldegrun disclaims beneficial ownership of the shares held by the Vida entities except to the extent of any pecuniary interest. The filing reports both sole and shared voting and dispositive powers for the aggregate position as set forth on the cover pages.

Positive

Reported beneficial ownership of 12,605,894 shares, representing 5.7% of outstanding common stock
Includes 3,243,004 shares issuable within 60 days upon exercise of stock options, explicitly disclosed in the filing

Negative

None.

Insights

TL;DR: Dr. Belldegrun reports 12,605,894 Allogene shares (5.7%), including 3,243,004 option shares exercisable within 60 days.

The Schedule 13G/A documents a material insider disclosure: an aggregate beneficial position of 12,605,894 shares versus 218,730,809 shares outstanding, equal to a reported 5.7% ownership stake. The position combines directly held shares, exercisable options and equity held through affiliated entities. Reported voting and dispositive powers are split between sole and shared authority, with the cover page showing 3,833,607 shares of sole voting power and 8,772,287 shares of shared voting power. This filing is primarily a transparency disclosure of ownership concentration and outstanding option exposure rather than an operational or financial development.

TL;DR: Multiple affiliated entities and a joint filing are used to report the position; Belldegrun disclaims certain beneficial ownership except for pecuniary interest.

The filing is structured as a joint filing across Dr. Belldegrun and several entities he manages or is affiliated with, including Bellco Legacy LLC/IV and Vida Ventures entities, and includes a Joint Filing Agreement. The document explicitly states disclaimers of beneficial ownership regarding Vida entities except for any pecuniary interest. Signatures are provided by Dr. Belldegrun in his individual and managerial capacities. From a governance perspective, the disclosure clarifies control lines and related-party holdings but does not indicate changes in board composition, corporate actions or voting commitments.

08/12/2025 - 04:57 PM

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 7)

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

019770106

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Allogene Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

210 East Grand Avenue, South San Francisco, CA, 94080.

Item 2.

(a)

Name of person filing:

Arie Belldegrun Bellco Legacy LLC Bellco Legacy IV LLC Vida Ventures LLC Vida Ventures III, L.P. Vida Ventures III-A, L.P.

(b)

Address or principal business office or, if none, residence:

Arie Belldegrun: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Bellco Legacy LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Bellco Legacy IV LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Vida Ventures LLC: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III, L.P.: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III-A, L.P.: 40 Broad Street, #201, Boston, MA 02109

(c)

Citizenship:

Arie Belldegrun: United States and Israel Bellco Legacy LLC: Delaware Bellco Legacy IV LLC: Delaware Vida Ventures LLC: Nevada Vida Ventures III, L.P.: Nevada Vida Ventures III-A, L.P.: Nevada

(d)

Title of class of securities:

Common Stock

(e)

CUSIP No.:

019770106

Item 4.

Ownership

(a)

Amount beneficially owned:

Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Belldegrun's cover page includes 3,243,004 shares of common stock issuable within 60 days of June 30, 2025 upon the exercise of stock options held by the Reporting Person and also includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 539,867 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun, (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), a limited liability company of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director, (d) 1,720,172 shares of common stock beneficially owned by Vida Ventures III, L.P. (Vida III), a limited partnership of which Vida Ventures GP III, LLC (Vida GP III) is the manager, of which Dr. Belldegrun is a Senior Managing Director, and (e) 3,965 shares of common stock beneficially owned by Vida Ventures III-A, L.P. (Vida III-A), a limited partnership of which Vida GP III is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, Vida III and Vida III-A, except to the extent of any pecuniary interest therein, and other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act.

(b)

Percent of class:

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 218,730,809 shares of common stock outstanding as of May 9, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 13, 2025.

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Arie Belldegrun, M.D.

Signature:	/s/ Arie Belldegrun
Name/Title:	Arie Belldegrun, M.D.
Date:	08/12/2025

Bellco Legacy LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By Arie Belldegrun, M.D., Manager
Date:	08/12/2025

Bellco Legacy IV LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By Arie Belldegrun, M.D., Manager
Date:	08/12/2025

Vida Ventures LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By VV Manager LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
Date:	08/12/2025

Vida Ventures III, L.P.

Signature:	/s/ Arie Belldegrun
Name/Title:	By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
Date:	08/12/2025

Vida Ventures III-A, L.P.

Signature:	/s/ Arie Belldegrun
Name/Title:	By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
Date:	08/12/2025

Exhibit Information

Joint Filing Agreement

Source:

FAQ

How many Allogene (ALLO) shares does Arie Belldegrun report beneficially owning?

The filing reports 12,605,894 shares beneficially owned by Dr. Arie Belldegrun.

What percent of Allogene does Dr. Belldegrun's holding represent?

The reported position represents 5.7% of Allogene's common stock based on 218,730,809 shares outstanding.

Are there option shares included in the reported holdings for ALLO?

Yes. The filing includes 3,243,004 shares issuable within 60 days upon exercise of stock options.

Which affiliated entities hold Allogene shares on behalf of Dr. Belldegrun?

Affiliated entities listed include Bellco Legacy IV LLC (4,710,120), Bellco Legacy LLC (539,867), Vida Ventures LLC (1,798,163), Vida Ventures III, L.P. (1,720,172), and Vida Ventures III-A, L.P. (3,965).

What voting and dispositive powers are reported in the filing?

The cover page reports 3,833,607 shares of sole voting power and 8,772,287 shares of shared voting power; sole and shared dispositive powers match those figures.

Does Dr. Belldegrun disclaim beneficial ownership of any shares?

Yes. He disclaims beneficial ownership of the shares held by the Vida entities except to the extent of any pecuniary interest.

AG真人官方

[SCHEDULE 13G/A] Allogene Therapeutics, Inc. SEC Filing

Insights

FAQ

How many Allogene (ALLO) shares does Arie Belldegrun report beneficially owning?

What percent of Allogene does Dr. Belldegrun's holding represent?

Are there option shares included in the reported holdings for ALLO?

Which affiliated entities hold Allogene shares on behalf of Dr. Belldegrun?

What voting and dispositive powers are reported in the filing?

Does Dr. Belldegrun disclaim beneficial ownership of any shares?

NASDAQ:ALLO

ALLO Rankings

ALLO Latest News

ALLO Latest SEC Filings

ALLO Stock Data

AG真人官方

Trending News

[SCHEDULE 13G/A] Allogene Therapeutics, Inc. SEC Filing

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

How many Allogene (ALLO) shares does Arie Belldegrun report beneficially owning?

What percent of Allogene does Dr. Belldegrun's holding represent?

Are there option shares included in the reported holdings for ALLO?

Which affiliated entities hold Allogene shares on behalf of Dr. Belldegrun?

What voting and dispositive powers are reported in the filing?

Does Dr. Belldegrun disclaim beneficial ownership of any shares?

NASDAQ:ALLO

ALLO Rankings

ALLO Latest News

ALLO Latest SEC Filings

ALLO Stock Data